TicoVac is the first vaccine available domestically to help protect adults and children who are visiting or living in TBE endemic areas, including deployed soldiers.
Dr. Abdulwasiu Bolaji Tiamiyu, Deputy Director of Research in Nigeria, in November graduated from the Harvard Medical School Global Clinical Scholars Training (GCSRT), an advanced training program research for clinicians and clinician-scientists around the globe.
SILVER SPRING, Md. – Some recent reports about Walter Reed Army Institute of Research’s COVID-19 Vaccine Development have led to inaccurate representations which require clarification. Last week, the preclinical results of the Army COVID-19 vaccine, SpFN, were published in Science Translational Medicine. The Spike Ferritin Nanoparticle platform is designed to protect against an array of SARS-CoV-2 variants and SARS-origin variants but was not tested on the Omicron variant.
SILVER SPRING, Md. – A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research (WRAIR) not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.
Dr. Kayvon Modjarrad was featured on Partnership for Public Service's podcast, Profiles in Public Service, where he discussed WRAIR's past infectious disease research efforts, WRAIR's COVID vaccine candidate SpFN and how to prepare for the next pandemic.
COVID-19 outbreaks in military populations threaten force health and readiness, and basic training presents particular challenges. A new publication co-authored by WRAIR scientists and posted on the preprint server medRxiv outlines improved strategies for preventing outbreaks during basic training, emphasizing the need for customized approaches in unique settings.
